Evidence map›Paper›PMID 34442744›Full record

ArticleMicroorganisms2021

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients.

Veronica Di Cristanziano, Patrick Affeldt, Moritz Trappe, Maike Wirtz, Eva Heger, Elena Knops, Rolf Kaiser, Dirk Stippel, Roman-Ulrich Müller, Udo Holtick and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Veronica Di CristanzianoInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany.ORCID 0000-0003-1604-8386
Patrick AffeldtDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.
Moritz TrappeInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany.
Maike WirtzInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany.
Eva HegerInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany.
Elena KnopsInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany.
Rolf KaiserInstitute of Virology, Faculty of Medicine, University Hospital Cologne, University of Cologne, Fürst-Pückler Straße 56, 50935 Cologne, Germany.
Dirk StippelDepartment of General, Visceral, Cancer and Transplant Surgery, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.ORCID 0000-0002-1107-0907
Roman-Ulrich MüllerDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.ORCID 0000-0001-6910-0745
Udo HoltickDepartment I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.
Christoph ScheidDepartment I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.
Martin KannDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.
Christine E KurschatDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.ORCID 0000-0002-3646-9471
Franziska GrundmannDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.ORCID 0000-0002-5766-7477
University of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment options for cytomegalovirus (CMV) infections in immunosuppressed patients are limited, mainly consisting of (val-)ganciclovir (VGC/GCV) as the first-line treatment. We report on three transplant recipients, one stem cell transplant (allo-HSCT) patient and two kidney transplant (KTx) recipients, with prolonged CMV viremia treated with a combined therapy based on letermovir (LMV), CMV-specific intravenous immunoglobulins (IVIg), and VGC/GCV, which led to the sustained control of CMV viremia in all patients.

Indexed as

bone marrowcellular responseCMVcombinationdrug resistanceELISPOTimmunosuppressionkidneyopportunistic infectiontransplantation

Identifiers

PMID34442744
PMCPMC8398864
OpenAlexW3188213930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.